Theravance Biopharma Inc (TBPH)
NasdaqGM · USD · Healthcare · Biotechnology
$17.03 (+0.00%) as of
Key statistics
- Market cap
- 884.18M
- P/E (TTM)
- 16.38
- Forward P/E
- 13.36
- EPS (TTM)
- 1.04
- 52-week range
- 13.08 – 21.03
- Beta
- 0.25
- Revenue (TTM)
- 104.31M
- Profit margin
- 51.58%
- Analyst target
- $17.67
- Volume
- 10.02M
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. As of September 23, 2026, Theravance Biopharma, Inc. operates as a subsidiary of Zymeworks Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- South San Francisco, CA, United States
- Employees
- 90
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.